Seattle Genetics, Inc.

Companies Invest in Antibodies That Fight Tumors

By Eileen Rojas - May 13, 2013 | Tickers: IMGN, RHHBY, SGEN

In the war against cancer, a new weapon holds promise to treat the disease in a novel way. ADCs, or antibody drug conjugates, use antibodies linked to potent anti-cancer therapeutic agents that deliver a better way of killing cancerous cells while minimizing side effects for patients. Clinical trials currently underway have so far shown very promising results.

How do ADCs work?

According to Dr. Marco Timmers, CSO at Synthon Biopharmaceuticals more »
Right Time To Buy This Pharmaceutical Company?

By Mike Thiessen - May 7, 2013 | Tickers: CYTR, PCYC, SGEN

Pharmacyclics (NASDAQ: PCYC) reported 1Q13 earnings on May 1, and the shares sold off 5.5% over the course of the day. The company fell short of analyst earnings and revenue forecasts. However, this could be a buying opportunity for investors, since most of the stock’s value is in future cash flows from a leukemia and non-Hodgkin lymphoma treatment that actually progressed faster than expected in the quarter.

Pharamcyclics more »
Mega-Hedge Fund Focusing on the Life Sciences

By Meena Krishnamsetty - April 18, 2013 | Tickers: GHDX, INCY, PCYC, SGEN, GEVA

The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization.

Why should you watch hedge funds?

Insider Monkey looks at 450 of the world’s most elite hedge fund managers and our research has shown that over time their picks routinely outperform. Let’s look at the top five picks more »
Mega-Hedge Fund Focusing on The Life Sciences

By Meena Krishnamsetty - April 16, 2013 | Tickers: GHDX, INCY, PCYC, SGEN, GEVA

The $3+ billion Baker Brothers Advisors equity portfolio, managed by brothers Julian and Felix Baker, focuses almost exclusively on life science companies with a small to medium sized market capitalization.

Why should you watch hedge funds?

Insider Monkey looks at 450 of the world’s most elite hedge fund managers and our research has shown that over time, their picks routinely outperform. For more than a decade in our back more »
This Biotech Stock Looks Like a Good Investment

By Terry Chrisomalis - April 6, 2013 | Tickers: IMGN, MRK, SGEN

The biotech sector is heating up with new technology platforms that are showing big promise. One such big promising technology comes from a company known as ImmunoGen (NASDAQ: IMGN). ImmunoGen uses a system called the "TAP" technology, also known as Targeted Antibody Payload.

Currently, antibodies are able to bind to cancer cells but have no effect on killing the target cancer cells. This is where ImmunoGen's technology comes into more »
Is It The Right Time For Immunogen?

By Terry Chrisomalis - April 3, 2013 | Tickers: IMGN, MRK, SGEN

The biotech sector is heating up with new technology platforms that are showing big promise. One such big promising technology comes from a company known as Immunogen (NASDAQ: IMGN). Immunogen uses a system called the "TAP" technology, also known as Targeted Antibody Payload. Currently antibodies are able to bind to cancer cells but have no effect on killing the target cancer cells. This is where Immunogen's technology comes into more »
Investing in a Cheap Life

By Marshall Hargrave - March 8, 2013 | Tickers: JNJ, LIFE, MRK, ONXX, SGEN

Life Technologies (NASDAQ: LIFE) appears to have lost its buyout premium, but is the stock still worth investing in? The stock fell 7% earlier this week after reports that the buyout buzz for the company was cooling off. The maker of genetic testing equipment was previously reported to have engaged Deutsche and Moelis & Company to help shop around. Meanwhile, parties potentially interested in scooping up the company included Blackstone and more »
Five Super Ideas in the Healthcare Sector

By Masam Abbas - February 12, 2013 | Tickers: LLY, FRX, MRK, REGN, SGEN

It will not be wrong if I state that healthcare is the most volatile sector in the world of equities. Drugs come and go. Some are rejected. Others are approved. Hence, the healthcare stocks keep on moving on such news. This sector is the absolute opposite of the transportation sector, which is/has been/will be transporting goods/people from one place to another and hence lacks the sense of more »
Baker Brothers Reports Stakes in InterMune and Repros Therapeutics

By Meena Krishnamsetty - February 5, 2013 | Tickers: ITMN, PCYC, RPRX, SGEN, GEVA

Baker Brothers, a healthcare focused hedge fund managed by Julian and Felix Baker, has recently filed with the SEC to disclose significant percentage stakes in two development stage biotechnology companies. The fund now owns 2.6 million shares of InterMune (NASDAQ: ITMN), giving it 3.3% of the outstanding shares of the stock, and 1.5 million shares, nearly 9%, of Repros Therapeutics (NASDAQ: RPRX).

InterMune’s focus is on more »
Celldex May Soar in 2013

By Michael Meyer - January 10, 2013 | Tickers: CLDX, SGEN

With so many companies claiming to have found the miracle cure for all diseases, it can be a tough challenge to find the contenders instead of the pretenders. But there is one company that appears to be getting closer to find the illusive treatment for breast cancer. That company is Celldex Therapeutics (NASDAQ: CLDX).

Celldex Therapeutics is a biopharmaceutical company focused on the development, manufacture, and commercialization of novel therapeutics more »
Six Disruptive Biotech Stocks

By Streetwise Reports - August 18, 2012 | Tickers: AVEO, DNDN, IMGN, SGEN, VRTX

By George S. Mack, The Life Sciences Report

For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

Imagine a novel discovery or even a novel platform that just fizzles. To a technology freak like me that sounds so disappointing to think that you can actually discover breakthrough ideas that are not disruptive and don't really change much. I recently spoke more »
J.P. Morgan Healthcare Conference Schedule: Day One

By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUS more »)